Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2016; 37(04): 314-318
DOI: 10.4103/0971-5851.195753
ASCO 2016 GI CANCER UPDATE

Focused update on Gastrointestinal (GI) Oncology from ASCO 2016

Ravi Kumar Paluri
GI Oncology, Department of Medicine, Division of Hematology Oncology, Associate Scientist, Experimental Therapeutics Program, Comprehensive Cancer Center, University of Alabama at Birmingham, AL, USA
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
12 July 2021

© 2016. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S et al.. Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. Journal of Clinical Oncology 2011;29:2011-19.
  • 2 Bokemeyer C, Staroslawska E, Makhson A, Bondarenko I, Hartmann JT, Shelygin Y, et al.. 3004 ORAL Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastastic colorectal cancer (mCRC): A large-scale phase II study, OPUS. European Journal of Cancer Supplements 2007;5:236.
  • 3 Humblet Y, Peeters M, Gelderblom H, Vermorken JB, Viret F, Glimelius B, et al.. 3017 POSTER Cetuximab dose-escalation in patients (pts) with metastatic colorectal cancer (mCRC) with no or slight skin reactions on standard treatment: Pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data from the EVEREST study. European Journal of Cancer Supplements 2007;5:240.
  • 4 European public assessment report-Vectibix. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000741/WC500183307.pdf. [Last updated on 2015 Feb, Last accessed on 2016 Sep].
  • 5 Lenz H, Niedzwiecki D, Innocenti F, Blanke C, Mahony MR, O'Neil BH, et al.. 501OCALGB/SWOG 80405: Phase III trial of Irinotecan/5-FU/LEUCOVORIN (FOLFIRI) or OXALIPLATIN/5-FU/LEUCOVORIN (MFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (PTS) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Ann Oncol 2014;25 Suppl 4:25. [Doi: 10.1093/annonc/mdu438.13].
  • 6 Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al.. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial. The Lancet 2001;358:1576-85.
  • 7 Berger AC, Garcia M, Hoffman JP, Regine WF, Abrams RA, Safran H, et al.. Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704. Journal of Clinical Oncology 2008;26:5918-22.
  • 8 Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, et al.. Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the U.S. Intergroup/RTOG 9704 Phase III Trial. Annals of Surgical Oncology 2011;18:1319-26.
  • 9 Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al.. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The conko-001 randomized trial. JAMA 2013;310:1473-81.
  • 10 Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, et al.. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: The ESPAC-3 periampullary cancer randomized trial. Jama 2012;308:147-56.
  • 11 Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.. Sorafenib in Advanced Hepatocellular Carcinoma. New England Journal of Medicine 2008;359:378-90.
  • 12 Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al.. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. The Lancet Oncology 2009;10:25-34.
  • 13 Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, et al.. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. New England Journal of Medicine 2006;355:11-20.
  • 14 Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al.. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-30.
  • 15 Rinke A, Wittenberg M, Schade-Brittinger C, Aminossadati B, Ronicke E, Gress TM, et al.. Placebo Controlled, Double Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results on Long Term Survival. Neuroendocrinology 2016.
  • 16 Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al.. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors. New England Journal of Medicine 2014;371:224-33.
  • 17 Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al.. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine 2015;372:2509-20.